Xoma | XOMA - Assets


Xoma reported $263.15M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Agenus USD 186.46M 40.34M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Ardelyx USD 504.51M 2.9M Mar/2026
aTyr Pharma USD 79.65M 435.68M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Celldex Therapeutics USD 511.25M 71.73M Mar/2026
Curis USD 19.97M 9.27M Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Incyte USD 7.34B 381.14M Mar/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 207.62B 542M Mar/2026
Prothena USD 349.89M 23.09M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Xoma USD 263.15M 39.7M Sep/2025